Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Score |
|---|
Hussain, 2020 [17] | Y | Y | N | Y | U | Y | N | Y | N | Y | N | 6 |
Jednacz, 2015 [18] | Y | Y | Y | Y | U | Y | N | Y | N | Y | N | 7 |
Pugliese, 2015 [20] | Y | Y | Y | Y | U | Y | N | Y | N | Y | N | 7 |
Gonçalves, 2007 [21] | Y | Y | N | U | U | Y | N | Y | N | Y | N | 5 |
Więch, 2018 [24] | Y | Y | N | Y | U | Y | N | Y | N | Y | N | 6 |
Bakkaloglu, 1996 [28] | Y | Y | N | U | U | Y | N | Y | N | Y | N | 5 |
Aranda-Valera, 2020 [30] | Y | Y | N | Y | U | Y | N | Y | N | Y | N | 6 |
- Note: (1) The data source was clear; (2) The inclusion and exclusion criteria of the exposed group and nonexposed group (case and control) were listed or referred to in previous publications; (3) The collection time of the research object was clear; (4) The research object was representative; (5) The measured variables were covered by other characteristics; (6) Describe any assessment to ensure quality; (7) The analysis results described the excluded objects; (8) Measures to evaluate and/or control confounding factors were described; (9) Describe the processing of lost data; (10) The response rate of patients and the integrity of data collection were summarized. 11. If there was a follow-up, the expected percentage of patients with incomplete data or follow-up results was written. Y: “Yes”; N: “No”; U: “Unclear”
Lipids in Health and Disease